<?xml version="1.0" encoding="UTF-8"?>
<document id="30166519">
	<sentence id="s1" text="MYCN activation, often due to genetic amplification, represents the driving oncogenic event for a number of human tumors, conferring bad prognosis and predicting very poor responses even to the most aggressive therapeutic protocols.">
		<entity id="s1.e1" charOffset="0-4"
			type="GENE" text="MYCN" ontology_id="4613"/>
		<entity id="s1.e2" charOffset="114-119"
			type="HP" text="tumor" ontology_id="HP_0002664"/>
		<entity id="s1.e3" charOffset="133-136"
			type="GENE" text="bad" ontology_id="572"/>
		<pair id="s1.p1" e1="s1.e1"
		    e2="s1.e2" pgr="true"/>
		<pair id="s1.p2" e1="s1.e2"
		    e2="s1.e3" pgr="false"/>
	</sentence>
	<sentence id="s2" text="Intriguingly, MRE11 is highly expressed and predicts bad prognosis in MYCN-amplified neuroblastoma.">
		<entity id="s2.e1" charOffset="14-19"
			type="GENE" text="MRE11" ontology_id="4361"/>
		<entity id="s2.e2" charOffset="70-74"
			type="GENE" text="MYCN" ontology_id="4613"/>
		<entity id="s2.e3" charOffset="85-98"
			type="HP" text="neuroblastoma" ontology_id="HP_0003006"/>
		<pair id="s2.p1" e1="s2.e1"
		    e2="s2.e3" pgr="false"/>
		<pair id="s2.p2" e1="s2.e2"
		    e2="s2.e3" pgr="false"/>
	</sentence>
	<sentence id="s3" text="Encapsulation of mirin in nanoparticles allowed its use on MYCN-amplified neuroblastoma xenografts in vivo, which resulted in a sharp impairment of tumor growth, associated with DDR activation, p53 accumulation, and cell death.">
		<entity id="s3.e1" charOffset="59-63"
			type="GENE" text="MYCN" ontology_id="4613"/>
		<entity id="s3.e2" charOffset="74-87"
			type="HP" text="neuroblastoma" ontology_id="HP_0003006"/>
		<entity id="s3.e3" charOffset="148-153"
			type="HP" text="tumor" ontology_id="HP_0002664"/>
		<pair id="s3.p1" e1="s3.e1"
		    e2="s3.e2" pgr="false"/>
		<pair id="s3.p2" e1="s3.e1"
		    e2="s3.e3" pgr="true"/>
	</sentence>
	<sentence id="s4" text="Therefore, we propose that MRE11 inhibition might be an effective strategy to treat MYCN-amplified and p53 wild-type neuroblastoma, and suggest that targeting replication stress with appropriate tools should be further exploited to tackle MYCN-driven tumors">
		<entity id="s4.e1" charOffset="27-32"
			type="GENE" text="MRE11" ontology_id="4361"/>
		<entity id="s4.e2" charOffset="84-88"
			type="GENE" text="MYCN" ontology_id="4613"/>
		<entity id="s4.e3" charOffset="103-106"
			type="GENE" text="p53" ontology_id="7157"/>
		<entity id="s4.e4" charOffset="117-130"
			type="HP" text="neuroblastoma" ontology_id="HP_0003006"/>
		<entity id="s4.e5" charOffset="251-256"
			type="HP" text="tumor" ontology_id="HP_0002664"/>
		<pair id="s4.p1" e1="s4.e1"
		    e2="s4.e4" pgr="false"/>
		<pair id="s4.p2" e1="s4.e2"
		    e2="s4.e4" pgr="false"/>
		<pair id="s4.p3" e1="s4.e3"
		    e2="s4.e4" pgr="false"/>
		<pair id="s4.p4" e1="s4.e1"
		    e2="s4.e5" pgr="true"/>
		<pair id="s4.p5" e1="s4.e2"
		    e2="s4.e8" pgr="true"/>
		<pair id="s4.p6" e1="s4.e5"
		    e2="s4.e8" pgr="true"/>
	</sentence>
</document>
